Compare stocks

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.